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Abstract 
The pore forming, Ca2+-dependent protein, perforin, is essential for the function of cytotoxic 
lymphocytes, which are at the frontline of immune defence against pathogens and cancer. 
Perforin is a glycoprotein stored in the secretory granules prior to release into the immune 
synapse. Congenital perforin deficiency causes fatal immune dysregulation, and is associated 
with various haematological malignancies. At least 50% of pathological missense mutations in 
perforin result in protein misfolding and retention in the endoplasmic reticulum. However, the 
regulation of perforin proteostasis remains unexplored. Using a variety of biochemical assays 
that assess protein stability and acquisition of complex glycosylation, we demonstrated that the 
binding of Ca2+ to the C2 domain stabilizes perforin and regulates its export from the 
endoplasmic reticulum to the secretory granules. Since perforin is a thermo-labile protein, we 
hypothesized that by altering its C2 domain it may be possible to improve protein stability. Based 
on the X-ray crystal structure of the perforin C2 domain, we designed a mutation (T431D) in the 
Ca2+ binding loop. Mutant perforin displayed dramatically enhanced thermal stability and lytic 
function, despite its trafficking from the endoplasmic reticulum remaining unchanged. 
Furthermore, by introducing the T431D mutation into A90V-perforin, a pathogenic mutation, 
which results in protein misfolding, we corrected the A90V folding defect and completely 
restored perforin’s cytotoxic function. These results revealed an unexpected role for the Ca2+-
dependent C2 domain in maintaining perforin proteostasis and demonstrated the possibility of 
designing perforin with supra-physiological cytotoxic function through stabilization of the C2 
domain.  
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Introduction 
 Cytotoxic T lymphocytes and natural killer cells recognize and destroy virus-infected and 
transformed cancerous cells through the exquisitely regulated secretory granule exocytosis 
pathway 1. Central to this mechanism is the pore-forming effector protein, Prf1 (Prf1), which is 
stored in cytotoxic secretory granules and co-secreted with the pro-apoptotic serine proteases, 
granzymes, into the immune-synapse formed between a cytotoxic lymphocyte and target cell 2. 
The high concentration of extracellular Ca2+ (>1mM) promotes binding of the Prf1 through its 
C2 domain to the target cell 3 via a single localized conformational change, which repositions 4 
key hydrophobic residues and promotes anchoring of Prf1 to the plasma membrane 4. Once 
bound, the neutral pH of the synapse facilitates Prf1 oligomerisation 5 into ring and arc-shaped 
pores 6, 7, which are required for the diffusion of granzymes into the cytoplasm of the target cell 
to initiate apoptosis 8. Prf1 therefore sits at the apex of the signaling cascade that triggers 
apoptotic target cell death and immune defense by cytotoxic lymphocytes.  
 The loss of perforin function due to bi-allelic mutations in the PRF1 gene leads to a severe 
and often fatal form of immune dysregulation, familial haemophagocytic lymphohistiocytosis 
(FHL) 9. If at least one of the affected alleles harbors a missense, hypomorphic mutation in PRF1, 
FHL may be delayed until adolescence or early adulthood, and there is also a high (up to 50%) 
risk of a haematological malignancy 10, 11. A significant proportion of these missense mutations 
lead to perforin misfolding and retention in the endoplasmic reticulum (ER) 12. Failure to traffic 
to the secretory granules results in failure of perforin secretion into the immune synapse and the 
loss of cytotoxic lymphocyte function. Similar to other protein misfolding diseases 13, perforin 
may partly recover its folding at permissive temperatures (for example, in vitro culture of 
cytotoxic lymphocytes at 30oC), with restoration of protein trafficking and cytotoxicity 12. 
However, recovery of function is typically incomplete and less likely with mutations associated 
with poor clinical outcomes. Over 30 of the reported pathogenic missense mutations in PRF1 
map to the C2 domain, consistent with an essential role of that domain in perforin function; 
these mutations often result in perforin misfolding. 
 The C2 domain of perforin can coordinate up to five Ca2+ ions, including two high-affinity 
sites II and V 3. Binding of Ca2+ to these two sites alone is not sufficient for membrane binding. 
In contrast, sites, I, III and IV bind Ca2+ at low affinity and are responsible for a conformational 
rearrangement of four conserved hydrophobic residues that are essential for perforin binding to 
the phospholipid bilayer 3. The ER maintains an ionic Ca2+ concentration sufficiently high (500-
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700µM) for Ca2+ binding and has neutral pH, and is the only intracellular compartment with an 
environment that may support perforin lysis. Indeed, we recently discovered that rapid export of 
perforin from the ER 14 and N-glycosylation close to the carboxy-terminus 15 are essential for 
protecting cytotoxic lymphocytes from their own endogenous perforin. As evidence, we showed 
that non-conservative mutations in a cryptic trafficking motif at the extreme C-terminus of 
perforin caused its retention in the ER and death of the killer cell; however introducing an 
additional mutation within the C2 domain to prevent Ca2+ binding restored cell viability without 
reversing the defect in trafficking. These observations clearly indicated that Ca2+ binds to the 
perforin C2 domain in the ER, but this does not compromise the viability or the effector function 
of the host cells. Intriguingly, it was recently found that physiological Ca2+ concentrations could 
stabilise perforin through the C2 domain 8, suggesting a role for Ca2+/C2 domain interaction 
beyond the regulation of perforin binding to the target cell membrane following exocytosis.   
In this study, we discovered that Ca2+-dependent stabilisation of perforin through the C2 
domain in the ER is required for its folding and the delivery to the secretory granules. 
Unexpectedly, we also identified a novel Ca2+ stabilizing mutation in the C2 domain that 
improved the kinetics of perforin pore formation and also enhanced its cytotoxicity to be greater 
than WT perforin; remarkably, it was also able to compensate for the folding and trafficking 
defect of a common disease-causing mutation, A90V. 
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Results 
Ca2+ binding to the C2 domain of perforin in the ER is required for its folding and trafficking.  
 We recently demonstrated that perforin is a thermodynamically labile protein, which 
acquired a more stable conformation at physiological Ca2+ concentrations; this effect of Ca2+ was 
abrogated by mutations in the C2 domain 4, 8. Given the high concentration of Ca2+ in the ER and 
the demonstrated ability of perforin to bind Ca2+ there 14, we hypothesised that Ca2+ binding to 
the C2 domain may play an important, previously unappreciated, role in perforin folding and 
export from the ER. 
 First, we substituted Ca2+-binding aspartate residues, D429 and D483, each of which is 
essential for Ca2+ binding and perforin function 6, 16 and located within distinct Ca2+-binding 
regions CBR1 and CBR2, respectively, with alanine (D429A and D483A) (Supplementary Figure 
1) 6, 16). These mutations completely abrogated perforin membrane binding and pore forming 
activity 16. As perforin traffics from the ER through the Golgi compartment, N-linked, high 
mannose glycans attached at residues N204, N375 and N548 progressively undergo complex 
glycosylation. Accordingly, perforin that is retained in the ER lacks complex glycans and remains 
sensitive to endoglycosidase H (EndoH) 14. We therefore assessed the EndoH resistance of WT 
and mutated perforins to determine their capacity to exit the ER.  
 Even though the expression levels of D429A and D483A were no different from WT, each 
demonstrated greater EndoH sensitivity than WT perforin (Figure 1A), indicating impaired 
export from the ER. In addition, simultaneously introducing both Ca2+ binding site mutations 
(D429A and D483A) did not further increase EndoH sensitivity, suggesting that failure to bind 
Ca2+ was sufficient to impair the export of the protein (Figure 1A). To further test the role of Ca2+ 
binding in conferring exit from the ER, we mutated D491 (D491A), a Ca2+-binding residue 
located in CBR3.  Previous studies have revealed that a mutation at this position does not 
abrogate Ca2+-dependent membrane binding and pore formation at physiological concentrations 
of Ca2+ 16. In contrast to D429A and D483A, D491A remained similarly resistant to EndoH as 
WT-perforin (Figure 1A).  
 Previously, we identified four hydrophobic residues (W427, Y430, Y486 and W488) that are 
key for interaction of the membrane proximal part of the C2 domain with the lipid membrane 4. 
Mutation of these residues does not impact on Ca2+ binding 3, 4. Accordingly, mutation of these 
four residues (W427A/Y430A/Y486A/W488A) did not impair mutant perforin export from the 
ER (Figure 1B). Taken together, these data suggest that it is the ability of the perforin C2 domain 
 6
to bind Ca2+, rather than the interaction with the ER membranes per se, which influenced 
perforin export.  
 In humans, hypomorphic perforin missense mutations that destabilize folding but retain 
partial function are commonly associated with haematological cancer in childhood or 
adolescence and/or atypical or delayed presentation with FHL 12, 17. These mutants are invariably 
retained in the ER and poorly exported to the secretory granules 12. By far the most common 
mutation of this type is the A91V variant (mouse homologue A90V; Figure 1C); this allele is 
carried in the heterozygous state by 8-9% of Caucasians. A91V homozygocity is strongly 
associated with leukemia/lymphoma, systemic inflammatory disorders and atypical FHL 2. As 
with human A91V 18, 19, 20, mouse A90V was partially misfolded and had a mild trafficking defect 
20, 21. To determine whether Ca2+ binding to perforin in the ER contributes to the stability of the 
A90V mutant, we combined A90V with mutations in critical Ca2+-binding residues in the C2 
domain described above, A90V/D429A, A90V/D483A and A90V/D491A. We found that the 
loss of Ca2+ binding (A90V/D429A or A90V/D483A) dramatically affected perforin stability and 
trafficking from the ER (Figure 1D). Indeed, the Endo H sensitivity of the double mutants 
exceeded the sum of A90V and Ca2+ binding mutants alone (A90V+D429A and A90V+D483A; 
Figure 1E and 1F dotted lines). Protein expression levels were also significantly reduced in 
comparison to WT-perforin. By contrast, mutation of the non-essential Ca2+-binding residue 
D491A (A90V/D491A), did not further increase the EndoH sensitivity of A90V (Figure 1G), 
indicating that the misfolding defect of A90V/C2 domain double mutants was directly associated 
with loss of Ca2+ binding at the C2 domain. Taken together, our results demonstrated that Ca2+ 
binding to the perforin C2 domain in the ER is required for stable folding and subsequent export 
of perforin from the ER.  
 
The folding and trafficking of A90V are rescued by Ca2+-dependent stabilisation through the 
perforin C2 domain. 
 The C2 domain of perforin differs from most others in that the overall affinity for Ca2+ is low. 
Unlike other C2 domains that avidly bind Ca2+ at low µM or even sub-µM concentrations, 
perforin becomes functional only at neutral pH and when free Ca2+ levels exceed 250µM, a 
concentration found only in extracellular milieu (for instance, in the immunological synapse) or 
in the ER of intact cells.  
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 Previously we have used NMR-based approaches, together with mutagenesis and 
crystallography, to demonstrate that the canonical Ca2+-binding site III has the weakest affinity 
of all five Ca2+-binding sites and is only filled at high concentrations of Ca2+ 3. These findings are 
consistent with our data revealing that CBR-1 must undergo significant conformational change 
in order to bring the key residues D429 and D435 into position to bind Ca2+. The rearrangement 
of CBR-1 further re-positions the four essential hydrophobic residues such that W427 and Y430 
are in close proximity to Y486 and W488.  Together these four hydrophobic residues are thus 
positioned to interact with the plasma membrane 4, 6.  
 We have previously suggested that the conformational change within CBR-1 is likely driven 
through electrostatic attraction to Ca2+ ions already bound at the high affinity sites I and II (since 
D429 also interacts with the site I and II and D435 interacts with site II).  Based on these data, we 
reasoned that introduction of additional negatively charged residues into CBR1 may facilitate 
conformational changes within CBR1 through provision of additional short or longer range 
electrostatic interactions with bound Ca2+ ions in site I and II. Accordingly, and using X-ray 
crystal structures that we had previously solved as a guide 3, 6, we identified T431 as one potential 
site to introduce a negatively charged residue into CBR1 and generated the mutation T431D. 
 Previously, we showed that the thermal stability of perforin is dramatically increased in the 
presence of Ca2+ 8. We therefore compared the thermal stability of the T431D variant to that of 
wild type perforin and found that the T431D substitution (Figure 2A) caused a dramatic increase 
in melting temperature at physiologically relevant concentrations of Ca2+.  Similar to WT, 
T431D-perforin stabilisation was Ca2+-dependent, as simultaneously mutating the key Ca2+-
binding residue D429 (D429A/T431D double mutant) prevented this change (Figure 2A). Taken 
together, these data suggested that as predicted, the mutation was in some way facilitating Ca2+ 
binding. 
 As discussed, we originally reasoned that the T431D variant may either interact directly with 
one of the bound Ca2+ ions or alternatively may facilitate conformational change in CBR1. To 
discriminate between these possibilities we determined the apo- and Ca2+-bound structures of a 
perforin C2 domain variant that contains the T431D mutation (mutant generated on the 
W427A/Y430A/Y486A/W488A background 3, 4) (Figure 3). In the absence of Ca2+, T431 is 
mobile and missing from the final model, whereas D431 is clear in the electron density (Figure 
3A). In the presence of added Ca2+ however the Ca2+ ions in sites I, II and III are conventionally 
coordinated by the same residues as in wild type protein, and the T431D position does not 
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directly interact with Ca2+. These data thus favour the idea that the T431D variant instead 
facilitates conformational change in CBR1, for example, through the provision of additional 
potential for long-range electrostatic interactions.  
 As we had shown Ca2+ binding in the ER regulates perforin folding and trafficking through 
stabilisation of its C2 domain, we hypothesized that T431D may potentially compensate for the 
misfolded phenotype of the A90V mutant. Due to folding defects of A90V, we were unable to 
produce sufficient amounts of the protein to assess its melting temperature, but we found that 
engineering the T431D mutation onto the backbone of A90V perforin (A90V/T431D) resulted 
in greater thermal stability than WT perforin (Figure 2A), and both T431D and A90V/T431D 
had a wild type level of cytotoxic activity (Figure 2B). Furthermore, in transiently transfected 
RBL cells, T431D improved EndoH sensitivity of A90V to the WT level (Figure 2C), suggesting 
that under steady-state conditions both folding and trafficking of A90V were restored. This 
process remained dependent on essential Ca2+-binding residue/s of the C2 domain, as further 
addition of the D429A mutation (A90V/D429A/T431D) destabilised the protein and completely 
abrogated trafficking improvements provided by T431D (Figure 2D). Furthermore, the 
D429A/T431D mutant was as sensitive to EndoH as the single D429A mutant, indicating once 
again that Ca2+ binding to the C2 domain of perforin in the ER was essential for the stabilizing 
properties of T431D (Figure 2D). From these results, we concluded that Ca2+-dependent 
stabilisation of the C2 domain in the ER is important for perforin folding, and subsequent 
trafficking to the secretory granules.  
  
T431D-Prf1 has supra-physiological function. 
 Similar to the ER, the synaptic cleft has neutral pH and high concentration of free Ca2+ 
(>1mM). We therefore investigated whether enhanced stabilisation of T431D-perforin also 
affected its lytic function. Using purified recombinant WT and T431D proteins, we found no 
significant difference in their ability to bind to membranes (Figure 4A), pore-size/geometry by 
negative stain EM (Figure 4B) or to synergise with granzyme B to induce target cell apoptosis 
(Figure 4C). However, target cell lysis at 1 mM Ca2+ was twice as fast with T431D-perforin as 
with WT (p<0.0005) (Figure 4D). Interestingly, at sub-physiological concentrations of Ca2+ 
(<0.5mM), both T431D and A90V/T431D had relatively lower cytotoxic activity than WT 
(Figure 4E). Speculatively, this may be due to the loss of CaIV, which is coordinated by D491 
(Figure 3).  
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 Next, we investigated the effect of the T431D mutation on perforin cytotoxicity in the 
context of an immune synapse using a standard RBL 51Cr release cytotoxicity assay 16. The results 
were surprising: T431D-expressing RBL cells had >5-fold superior cytotoxicity in comparison to 
killer cells expressing WT perforin (Figure 5A), in that over 5-times fewer killer cells expressing 
T431D-perforin were required to produce an equivalent level of 51Cr release (cell death). We also 
considered the possibility that overexpression of perforin in this experiment would potentially 
result in saturation of the cell death readout. Since perforin cDNA was cloned into pIRES-eGFP 
vector and transiently transfected into RBL effector cells, we sorted high and low perforin-
expressing cells (based on eGFP fluorescence intensity) and assessed their cytotoxic activity 
separately. The cells expressing relatively low levels of T431D had >10-fold greater cytotoxicity 
than the cells expressing an equivalent amount of WT perforin (Figure 5B). This was not due to 
an increased affinity of the C2 domain for Ca2+, as T431D was only cytotoxic at physiologically 
relevant concentrations of Ca2+, and only displayed augmented cytotoxicity within the range of 
Ca2+ concentrations that corresponded with enhanced stability (Figure 5C).  
 Finally, we investigated whether improved folding or trafficking through Ca2+-dependent 
stabilisation could also rescue A90V function. We found that this was indeed so: A90V/T431D 
cytotoxicity was significantly improved, above that of WT perforin (Figure 5D), which was likely 
due to a combination of improved folding (Figure 2A-C) and more rapid pore-formation (Figure 
4D). To determine whether T431D facilitated trafficking of the A90V mutant, we assessed the 
rate of perforin export from the endoplasmic reticulum. Thus RBL cells were transiently 
transfected with perforin variants, and the rate of acquisition of complex glycosylation (EndoH 
resistance) over 90-240 minutes was a measure of perforin export from the ER and processing in 
the Golgi. The experiment demonstrated that the rate of trafficking of T431D was slightly higher 
than that of WT, but it did not improve the rate of A90V export from the endoplasmic reticulum 
(Figure 5E).  
 Overall, the results of this study demonstrate that Ca2+-dependent stabilization of perforin 
through the C2 domain is required for its folding, function and proteostasis in general. 
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Discussion 
 The current study uncovered a novel and critical role for the C2 domain in maintaining Prf1 
proteostasis. This was demonstrated using a dual approach, where we first improved and then 
abrogated Ca2+ binding to the C2 domain of Prf1. Remarkably, by engineering a new Ca2+-
stabilising mutation in the C2 domain of Prf1 (T431D), we produced a ‘‘super-Prf1’’, which had 
significantly higher cytotoxic activity than wild-type perforin. In addition, this mutant stabilized 
and rescued the delivery of a partially misfolded, common pathological mutant, A90V, to the 
secretory granules. In a reciprocal series of experiments, the abrogation of C2 domain function 
through mutation of critical Ca2+ binding aspartate residues resulted in a significant decrease in 
the delivery of A90V Prf1 to the secretory granules. Given that A90V is not part of the C2 
domain, and its location is approximately 120Å away from the Ca2+-binding regions 6, it 
appeared that Ca2+-dependent stabilisation of the C2 domain was critical for the efficient folding 
and export of Prf1 from the ER. It is unclear why T431D-perforin enhances the stability and 
function of perforin, but the X-ray crystal structure suggests that this may be due to additional 
long-range electrostatic interactions within the C2 domain. Interestingly, we found that T431D 
had reduced cytotoxic activity at sub-physiological Ca2+ concentrations and that under our 
crystallization conditions it was missing one Ca2+ (CaIV) that was coordinated by D491. We are 
led to speculate that there may be a link between the two phenomena, as we showed previously 
that the D491A mutation had no effect on perforin function at physiological concentrations of 
Ca2+, but the activity of the mutant was impaired at low (non-physiological) Ca2+ levels 16.  
 An increase in Prf1 stability through Ca2+ binding to the C2 domain also provided an 
oligomerisation advantage, whereby T431D could lyse cells at a faster rate than WT Prf1 to 
confer both augmented cytotoxicity and recovery of oligomerisation deficiencies. These results 
suggest that the more stable T431D Prf1 may be ‘primed’ for more efficient oligomerisation and, 
potentially, pore formation. This concept is supported by previous studies, which have reported 
that WT Prf1 becomes significantly more stable under conditions that favour Prf1 pore 
formation within the immunological synapse 4, 8. Taken together, it appears that in addition to 
Ca2+-dependent membrane binding 16, stabilisation of the C2 domain of WT Prf1 may be a 
previously unrecognized step required for pore formation.  
 The C2 domain of Prf1 is unique, with a relatively low affinity for Ca2+ in comparison with 
intracellular C2 domain proteins, which respond to submicromolar fluctuations in Ca2+ 
concentrations in order to become activated. Although the neutral pH and high concentration of 
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Ca2+ in the ER create a favorable environment for perforin lethal pore-forming activity, cytotoxic 
lymphocytes can rapidly export it through the Golgi to the acidic secretory granules 14. In 
addition, the C-terminal glycosylation protects the cell from perforin toxicity within the 
endoplasmic reticulum 15. The results of our study indicate that, paradoxically, the high level of 
Ca2+ in the ER promotes Prf1 stabilisation, which is necessary for efficient protein folding and 
trafficking. Unlike high affinity calcium binding sites II and V, which are likely to be 
constitutively occupied, low affinity Ca2+ binding sites I, III and IV act as a chemical sensor that 
only responds to high Ca2+ concentrations 4. Once the protein has been folded and exported from 
the ER, it likely becomes functionally inert in the low Ca2+ environment of the Golgi and acidic 
pH of the secretory granules, where it is unable to oligomerise and insert into the membrane 8. 
Overall, Ca2+ binding to the C2 domain plays a critical role in the proteostasis of Prf1, which 
requires a precise balance between Ca2+ and membrane binding, folding in the ER, export to the 
Golgi, and cytotoxic lymphocyte toxicity.  
 It is well established that disease-causing Prf1 mutations are the result of protein misfolding 
in the ER 12. Our discovery that Prf1 folding in the ER is Ca2+-dependent provides a rationale for 
the development and application of specific drug therapies for FHL caused by Prf1 deficiency. 
Patients with late-onset FHL2 often require aggressive cytotoxic drug therapy in order to treat 
the disease prior to bone marrow transplantation. Alternative therapies that modify the 
proteostasis network through a post-translational mechanism 21, 22 are significantly less aggressive 
and may provide a more suitable alternative to initial treatment. Such an approach would 
facilitate targeting of Prf1-expressing lymphocytes without damaging other cell types, and will be 
the focus of ongoing studies. 
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Materials and Methods 
Expression and Binding of Recombinant perforin. 
 Mouse perforin mutants were expressed and purified using a baculovirus expression system 
as previously described 23.  Lytic activity were assessed using sheep erythrocytes (SRBC), and cell 
death resulting from the synergistic effects of perforin and granzyme B (GzmB) was assessed by 
51Cr release assays 24. Membrane binding was assessed by incubating perforin and SRBCs in 
10mM Hepes, 150mM NaCl, pH 7 with or without 1mM Ca2+ at 4C for 15 min, followed by 4 
subsequent washes in Ca2+-free buffer. The thermal stability of purified recombinant mouse WT 
and mutant perforin was assessed by unfolding temperature analysis using SYPRO Orange 4.  
 
Transient Transfection of Cell Lines and Cytotoxicity Assays 
 Rat Basophil Leukemia cells RBL-2H3 (RBL) and Jurkat human T leukemia target cells were 
maintained in culture as previously described 23. Point mutations in mouse WT perforin cDNA 
were generated using the QuikChange site-directed mutagenesis system and cloned into the 
pIRES-EGFP expression plasmid (Biosciences Clonech). The WT and mutant perforin plasmids 
were transiently transfected into RBL cells, which were sorted by flow cytometry for equal mean 
GFP fluorescence 24 hr later, with subsequent assessment of cytotoxic activity in 51Cr release 
assays with Jurkat T cells 23. Perforin expressing RBL cells sorted by flow cytometry for equal 
mean GFP fluorescence were also used for Western Immunoblot (see below). 
 
Electrophoresis and Immunoblotting 
 Whole cell lysates, SRBC membranes and purified recombinant mouse perforin were 
prepared in NP40 lysis buffer (250 mM NaCl, 25 mM HEPES, 2.5 mM EDTA, 1% [v/v] NP-40, 
supplemented with protease inhibitors cocktail (Roche Life Sciences)). EndoH and PNGaseF 
glycosidase treatment was conducted according to the manufacturer’s instructions (New 
England Biolabs). Protein lysates were separated on 4-12% Nu-Page Bis-Tris gradient gels 
(Invitrogen) and immunoblotted with rat anti-perforin mAb P1-8 (provided by Kyowa Kirin) 
followed by secondary HRP-linked anti-rat antibody. The loading control used for cell lysates 
was mouse anti-human actin mAb (Sigma) followed by secondary HRP-linked anti-mouse Ig 
(Dako). Signals were amplified by chemiluminescence and detected on X-ray film (GE 
Healthcare). ImageJ software (ImageJ 1.475v, NIH) was used for quantitative densitometry.  
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Negative stain electron microscopy sample preparation. 
 Purified recombinant WT and T431D perforin pores were formed on DMPC/cholesterol 
lipid monolayers as described 6. Images were collected on a Gatan 4k X 4k CCD camera (15μm 
per pixel) on a Tecnai F20 microscope (FEI) at 200keV and 67,000X magnification. 
 
Crystallography. 
 Recombinant perforin C2 domains (residues 410-535) were expressed and purified from 
E coli as described before 3. A mutant form, which carries four amino acid substitutions 
(W427A/Y430A/Y486A/W488A, C2_T431) was used for the current studies to generate 
C2_D431. C2_T431D was crystallised in 0.2M Ammonium iodide, 20% PEG 3350 in the absence 
of added Ca2+, or in 0.1 M MgCl2, 0.1 M Na-HEPES pH7.5 and 10% w/v PEG 4000 in the 
presence of 1mM Ca2+ (Table 1). The crystals were flash-cooled in liquid nitrogen using 25% 
(v/v) glycerol as the cryoprotectant. Data sets were collected at the Australian Synchrotron MX2 
beamline at 100K. The data were merged and processed using XDS 25, POINTLESS 26 and 
SCALA 27 or AIMLESS 28. Five per cent of the data set was flagged as a validation set for 
calculation of the Rfree. Molecular replacement (MR) was carried out using wild-type perforin 
structure 3NSJ as a search probe 29  One molecule was found per asymmetric unit cell and an 
initial model was generated using PHASER. Model building was performed using COOT 30 and 
refinement was performed using BUSTER (Cambridge, United Kingdom: Global Phasing Ltd). 
Crystallographic and structural analysis was performed using the CCP4 suite 27 unless otherwise 
specified. The figures were generated using MacPYMOL (The PyMOL Molecular Graphics 
System, Version 1.2r3pre, Schrödinger, LLC.) and the structural validation was performed using 
MolProbity 31. All atomic coordinates and structural factors were deposited in the PDB under 
codes 5UG6 (in the absence of Ca2+) and 5UG7 (in the presence of Ca2+). 
 
Statistical Analysis 
The statistical analyses used were: paired t-test (when comparing two groups); or one-way 
ANOVA with Tukey’s post-hoc analysis (when comparing more than two groups). The 
application of each test is indicated in the figure legends. A non-linear regression analysis was 
applied to all SRBC lysis assays and 51Cr release killing assays for clarity. 
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Figure Legends 
Figure 1: Ca2+-dependent stabilisation of the C2 domain is necessary for efficient perforin folding 
and export from the ER. 
(A) Western immunoblot demonstrates the relative perforin expression in each of the transiently 
transfected RBL cell populations (WT, D429A, D483A, D491A) in the presence of EndoH (+) or 
buffer only control (-). EndoH sensitive bands are highlighted by (*). The bar graph shows 
quantitative densitometry of the EndoH treated (+) protein lysates; mutation of essential Ca2+ 
binding residues causes a significant increase in % EndoH sensitive Prf1. EndoH sensitivity was 
calculated using the % EndoH cleaved protein versus the total amount of protein (cleaved and 
uncleaved) as detected by the PI-8 antibody. Shown is mean ± SEM of at least 3 independent 
experiments and statistics were determined using ANOVA and Tukey’s post-hoc analysis, *p < 
0.05. 
(B) Western immunoblot using the P1-8 antibody demonstrates the relative perforin expression 
in RBL cells transiently transfected with WT and the W427A/Y430A/Y486A/W488A quadruple 
mutant (x4) in the presence of EndoH (EH), PNGaseF (PF) or buffer only control (Con); the 
EndoH sensitivity of the x4 Prf1 was indistinguishable from WT.  
(C) Western immunoblot using the P1-8 antibody demonstrates the relative perforin expression 
in RBL cells transiently transfected with WT and the A90V mutant in the presence of EndoH (+) 
or buffer only control (-). EndoH sensitive bands are highlighted by (*). The bar graph shows 
quantitative densitometry of the EndoH treated (+) protein lysates; the mildly misfolded A90V 
Prf1 mutant caused a significant increase in % EndoH sensitive Prf1. EndoH sensitivity of WT 
and A90V perforin was calculated as described in Figure 1A. Shown is mean ± SEM of n=16 
(WT) and n=7 (A90V) independent experiments and statistics were obtained with an unpaired 
two-sample for means t-test, *p < 0.05. 
(D) Western immunoblot using the P1-8 antibody demonstrates the relative perforin expression 
in each of the transiently transfected RBL cell populations (WT, A90V/D429A, A90V/D483A, 
A90V/D491A) in the presence of EndoH (+) or buffer only control (-).EndoH sensitive bands 
are highlighted by (*). Shown is mean ± SEM of at least 3 independent experiments. 
(E-G) Bar graphs showing quantitative densitometry of the EndoH treated (+) protein lysates 
from representative westerns in Figure 1C and 1D. To determine whether the double mutation 
of A90V and Ca2+ binding residues (A90V/D429A, A90V/D483A, A90V/D491A) had a 
synergistic effect on perforin stability and trafficking from the ER above normal background 
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levels, the % EndoH sensitive WT Prf1 was subtracted from the % EndoH sensitivity of perforin 
mutants. Dotted bars show predicted additive effect of individual mutants. Each value represents 
± SEM for at least three independent experiments. The statistical significance was determined 
using ANOVA and Tukey’s post-hoc analysis, *p < 0.05. 
 
Figure 2: Prf1 protein is stabilized by a point mutation, T431D, in the C2 domain in the presence 
of Ca2+.  
(A) The thermal melting temperature of WT and mutant Prf1 in the presence of increasing Ca2+ 
concentrations: (left, WT and T431D Prf1) T431D Prf1 was significantly more stable than WT 
Prf1 in the presence of >1mM Ca2+; (center, WT and D429A/T431D Prf1) inhibition of Ca2+ 
binding to the Prf1 C2 domain by D429A prevented any increase in T431D Prf1 thermal 
stability; (right, WT and A90V/T431D Prf1) the T431D mutation onto the backbone of A90V 
perforin resulted in greater thermal stability than WT perforin. Each value represents means ± 
SEM for three (left and center) or five (right) experiments, and statistics were obtained with an 
unpaired two-sample for means t test *p < 0.05. 
(B) There was no significant difference in the lytic activity of recombinant WT and T431D Prf1 
(left) and A90V/T431D Prf1 (right), as assessed using SRBCs.  
(C) Western immunoblot using the P1-8 antibody demonstrates the relative Prf1 expression in 
each of the transiently transfected RBL cell populations (WT, T431D, A90V and A90V/T431D) 
in the presence of EndoH (+) or buffer only control (-). Endo H sensitive band is highlighted by 
(*). The bar graph shows densitometry analysis of the EndoH treated (+) protein lysates; the 
T431D mutation restored the % EndoH sensitivity of A90V to WT Prf1 levels (A90V/T431D). 
EndoH sensitivity of perforin was calculated as described in Figure 1. WT and A90V values 
(dotted lines) are reproduced from Figure 1C (WT, n=16, A90V, n=7); n=3 for T431D and 
A90V/T431D. Statistical significance was determined using ANOVA and Tukey’s post-hoc 
analysis, *p < 0.05. 
(D) Western immunoblot using the P1-8 antibody demonstrates the relative Prf1 expression in 
each of the transiently transfected RBL cell populations (WT, D429A/T431D, 
A90V/D429A/T431D) in the presence of EndoH (+) or buffer only control (-). The bar graph 
shows densitometry of the EndoH treated (+) protein lysates; T431D Prf1 did not restore the % 
EndoH sensitivity to WT levels in the presence of the D429A Ca2+ binding mutation. EndoH 
sensitivity of perforin was calculated as described in Figure 1A. D429A and A90V/D429A values 
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(dotted lines) are reproduced from Figure 1E. Each value represents ± SEM for at least three 
independent experiments and statistics were determined using ANOVA and Tukey’s post-hoc 
analysis, nsd: no significant difference.  
 
Figure 3. Crystal structure of T431 Prf1 reveals conformational changes in the Calcium Binding 
Regions (CBRs). 
Superposition of C2 domains crystal structures. A. C2 domain of full-length perforin (PDB ID 
3NJS, grey), C2_T431 (PDB IB 4Y1S, cyan, left) and C2_D431 (skyblue, right), No Ca2+ was 
added to the sample buffers or cyrstallization buffers (see Materials and Methods). Also shown 
are high affinity Ca2+ ions in the structures, presumably scavenged from the growth media, they 
are found in sites II and V of 3NJS, site V of C2_T431; no Ca2+ is found in the C2_D431 
structure. All Ca2+ ions shown are coloured according to the corresponding C2 structures. 
Residues 433-438 of C2_T431 are missing from the electron density map and are represented as 
a red dashed line (left). B. Crystal structures of C2 domains C2_T431 (PDB ID 4Y1T, cyan, left 
and bottom) and C2_D431 (skyblue, right and bottom) obtained in the presence of added Ca2+. 
Also shown is the C2 domain of full-length perforin (PDB ID 3NJS, grey, left and right) as for A. 
The structure of C2_D431 reveals three Ca2+ ions (CaI-III), whereas five Ca2+ ions can be 
observed in the structure of C2_T431. Also shown are residues D429, D483, D491, CBR 1-3 and 
loop 510-515 and distances between CaI and D429 and D491 (in angstrom, red). 
 
Figure 4: Stabilisation of Prf1 with T431D increased the rate of target cell lysis. 
(A) Binding of recombinant WT and T431D perforin to SRBC membranes. There was no 
significant difference in the amount of T431D perforin bound to SRBC membranes in 1mM Ca2+, 
or avidity of membrane binding, as detected by western blot after washing in Ca2+-free buffer.  
(B) Negative stain electron microscopy images of Prf1 oligomers on lipid monolayers. T431D 
oligomerises into arcs and rings similar to WT Prf1. Scale bar, 20 nm.  
(C) Prf1/GrzmB synergy is not affected by stabilisation of Prf1 with T431D. HeLa cells were 
treated with sublytic Prf1 in the absence (Prf1 only) or presence of 2, 3 and 5 μg of GrzmB and a 
4 h 51Cr release assay was performed. Each value is ± SEM of three replicates, and is 
representative of 2 independent experiments. Statistics were obtained using unpaired t-test, ns: 
no significant difference.  
(D) The rate of SRBC lysis was increased almost 2-fold by stabilisation of Prf1 with T431D. 5x108 
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SRBCs/ml were incubated with purified recombinant mouse WT and T431D Prf1 in 1mM Ca2+ 
at 37°C. The SRBC/Prf1 reaction was quenched with ice-cold EDTA after 30 sec, 1, 2, 3, 4, 5, 10 
and 15 mins. All values have been normalized against maximum lysis observed at 15 mins 
(100%); average maximum lysis was WT: 73.0 ± 10.0 SEM (n=7) and T431D: 74.6 ± 12.2 SEM 
(n=7). Dotted lines represent the time required to achieve 50% maximum cell lysis: 4.9±0.4min 
and 2.5±0.3min (mean±SEM, n=7 independent experiments; p<0.0005 unpaired t-test) for WT 
and T431D, respectively. 
(E) The lytic activity of recombinant WT and T431D Prf1 (left) and A90V/T431D Prf1 (right) in 
the presence of increasing Ca2+ concentrations was assessed using SRBCs. At sub-physiological 
Ca2+ concentrations of <0.5mM, T431D and A90V/T431D had relatively lower cytotoxic activity 
than WT Prf1. 
  
Figure 5: Stabilisation of Prf1 with T431D increases cellular cytotoxicity. 
(A) Cytotoxicity of transiently transfected RBL cells expressing WT and T431D Prf1, as 
determined by 51Cr release assay using Jurkat T-cells as targets, at the effector/target (E:T) ratios 
indicated (100% WT average maximum lysis at 30:1 E/T ratio was 42 ± 5 SEM). The data was 
fitted to Michaelis-Menten kinetics (using Prism 7.0.c). Using Michaelis-Menten equation, it was 
calculated that T431D required 4.9 effector cells (while WT required 30 effector cells) to achieve 
100% lysis. Therefore, killer cells expressing T431D were 6.1-times more efficient than WT cells 
in producing an equivalent level of 51Cr release (dotted lines). Each value represents mean ± SEM 
of three independent experiments. 
(B) Cytotoxicity of transiently transfected RBL cells expressing WT and T431D Prf1 sorted for 
high and low GFP fluorescence, as determined by 51Cr release assay using Jurkat T-cells as targets, 
at the effector/target (E:T) ratios indicated (100% WT average maximum lysis at 30:1 E/T ratio 
was 47.1 ± 11.5 SEM). The cytotoxicity of T431D was increased ~10-fold in low GFP expressing 
cells when compared with WT Prf1. Each value represents mean ± SEM of three independent 
experiments. Western immunoblot using the P1-8 antibody demonstrated equivalent protein 
expression of WT and T431D Prf1 in low and high GFP expressing RBL cells.  
(C) Cytotoxicity of transiently transfected RBL cells expressing WT and T431D Prf1, at 
increasing concentrations of Ca2+, as determined by a 51Cr release assay using Jurkat T-cells as 
targets, at a constant effector target (E:T) ratio of 30:1. Ca2+ was quenched from DMEM media 
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using EGTA. Each value is mean ± SEM of three replicates, and is representative of 2 
experiments.  
(D) Cytotoxicity of transiently transfected RBL cells expressing WT, T431D, A90V and 
A90V/T431D Prf1, as determined by 51Cr release assay using Jurkat T-cells as targets, at the 
effector/target (E:T) ratios indicated (100% WT average maximum lysis at 30:1 E/T ratio was 50 
± 6% SEM). The A90V/T431D Prf1 had ~5-fold increase in cytotoxicity when compared with the 
disease causing mutant, A90V, alone. Each value represents mean ± SEM of three independent 
experiments. 
(E) Wild-type or mutant perforin was transiently transfected (by electroporation) into RBL cells, 
plated and grown for 90-240 minutes. At the time-points shown above the Western blot (on the 
left), the cells were harvested by trypsinisation and the lysates were treated with EndoH to 
determine a relative proportion of EndoH-resistant (upper bands) and EndoH sensitive (lower 
band) perforin. The migration of deglycosylated perforin was determined by treating the lysate 
from a sample collected at 240min with PNGaseF (shown as ‘‘F’’) on the Western blot. ‘‘UT’’ 
indicates an untreated lysate. The ratio of upper and lower bands was determined from three 
independent experiments; plotted is an acquisition of EndoH resistance over time (mean ± SEM). 
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Table 1. Data collection and refinement statistics* 
 
 C2_T431D1 C2_T431D_Ca2 
Data collection   
Space group P212121 I121 
No mol/au 
1 1 
Cell dimensions     
    a, b, c (Å) 27.77 66.03 74.9 51.00 31.31 86.36 
  α, β, γ  (°)  90, 90, 90 90, 101.35, 90 
Resolution (Å) 33.01 (2.00) 42.34 (1.80) 
Rmerge /Rpim 1.514 / 0.604 0.408 / 0.360 
I/sI 2.6 2.5 
Completeness (%) 100 (100) 99.3 (88.6) 
Redundancy 7.0 (7.3) 4.1 (3.5) 
Refinement   
No. reflections  
(work/free) 
2591/115 2829/145 
Rwork/ Rfree 19.1/22.2 21.1/23.3 
No. atoms   
    Protein 956 980 
    Ligand/ion 1 3 
    Water 70 90 
B-factors   
    Protein 30.21 30.21 
    Ligand/ion 19.28 18.99 
    Water 32.95 35.59 
r.m.s deviations   
    Bond lengths (Å)  0.010 0.010 
    Bond angles (°) 1.12 1.09 
MolProbity analysis 
     Ramachandran 
outliers 
     Ramachandran 
favoured 
     MolProbity score 
 
0% 
 
96.64% 
 
100% 
 
0% 
 
93.14% 
 
100% 
*Highest resolution shell is shown in parenthesis. 
1Structure consists of residues 410-427, 431-535. 
2Structure consists of residues 410-535. 
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